scholarly journals 988P Ocular complications of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: A multi-center prospective observational cohort study

2021 ◽  
Vol 32 ◽  
pp. S844
Author(s):  
K.S-K. Ma ◽  
H.N. Saeed ◽  
J. Chodosh
Keyword(s):  
Cohort Study ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Observational Cohort Study ◽  
Stevens Johnson Syndrome ◽  
Prospective Observational Cohort Study ◽  
Ocular Complications ◽  
Johnson Syndrome ◽  
Observational Cohort

Late-onset Stevens–Johnson syndrome due to nivolumab use for hepatocellular carcinoma

2019 ◽  
Vol 25 (8) ◽  
pp. 2052-2055 ◽  
Author(s):  
Constantin A Dasanu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Side Effects ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Late Onset ◽  
Checkpoint Inhibitor ◽  
Stevens Johnson Syndrome ◽  
Erythematous Rash ◽  
Immunoglobulin G4 ◽  
Johnson Syndrome

Nivolumab is a fully human immunoglobulin G4 immune checkpoint inhibitor antibody approved for use in the treatment of several malignancies. Severe side effects such as Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) have only extremely rarely been reported with this drug. We present herein a patient who developed SJS after 16 weeks of therapy with nivolumab. A week prior to this event, he developed a pruriginous papulo-erythematous rash. Prompt recognition of this phenomenon, immune checkpoint inhibitor discontinuation and steroid therapy are necessary steps in order to avoid dismal outcomes.

Sign in / Sign up

Export Citation Format

Share Document